- German biopharmaceutical company BioNTech partnered with Pfizer on the development of an mRNA vaccine for the novel coronavirus.
- Their product reached the clinical phase trial stage, with Phase 1/2 testing already underway in Germany and the US.
- The first American volunteers will soon enroll in the trial, and the two companies say they may be able to manufacture hundreds of millions of doses next year, assuming the drug works.
- Visit BGR’s homepage for more stories.
115 teams were working on COVID-19 vaccine candidates as of mid-April, according to Bill Gates, and some of those drugs have already reached human trials. Just last week, we learned of a company from German that started trials on an mRNA vaccine. BioNTech’s BNT162 is the compound in question, and the company partnered with pharmaceutical Pfizer to expand testing and manufacturing.
The two parties on Tuesday announced that the Phase 1/2 trial of BNT162 will start in the US as well. Assuming the drug can generate the desired immune response preventing infection with the novel coronavirus, millions of doses of the vaccine might be ready for emergency use this year, and hundreds of millions of doses could be mass-produced in 2021.
Today’s Top Deals
- Someone reverse-engineered N95 face masks: Here’s how to make your own
- 10 Amazon deals that are only available to Prime members
- Today’s best deals: 80¢ face masks, KN95 masks in stock, hand sanitizer, AirPods 2 blowout, $8 wireless charger, more
Trending Right Now:
- Here’s when the next round of coronavirus stimulus checks will arrive
- Scientists finally explained one of the strangest coronavirus symptoms
- Cinco de Mayo 2020 deals: All the best freebies and discounts
Another coronavirus vaccine is starting clinical trials in the US originally appeared on BGR.com on Tue, 5 May 2020 at 20:11:44 EDT. Please see our terms for use of feeds.
Read more here:: Boy Genius Report